Rebecca Fojas-Calimpong
Primary Care · Honolulu, HINPI 1437654308
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,801, 7.2 times the $250 reported in 2021.
Across 259 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$1K
- Gilead$1K
- AbbVie$666
- Otsuka America Pharmaceutical, Inc.$595
- Alkermes, Inc.$451
- Novo Nordisk$400
- plus $1K from 12 others
What the payments were for
- Food & beverage$6,038100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 56 | $1,281 |
| Gilead | 95 | $1,209 |
| AbbVie | 23 | $666 |
| Otsuka America Pharmaceutical, Inc. | 17 | $595 |
| Alkermes, Inc. | 14 | $451 |
| Novo Nordisk | 5 | $400 |
| Teva Pharmaceuticals USA, Inc. | 23 | $376 |
| Viiv Healthcare Company | 3 | $173 |
| Johnson & Johnson(2 entities) | 7 | $145 |
| Abbott | 2 | $143 |
| Amgen | 1 | $122 |
| Amarin Pharma, Inc. | 2 | $120 |
| Lundbeck LLC | 5 | $119 |
| Intercept Pharmaceuticals, Inc. | 1 | $118 |
| GSK | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| EMD Serono, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$473
- LYBALVI$470
- ABILIFY MAINTENA$270
- ABILIFY ASIMTUFII$270
- FREESTYLE LIBRE 3$129
- Mavyret$125
- DALVANCE$125
- RYBELSUS$125
- PERSERIS$125
- EVENITY$122
- Yeztugo$119
- ARISTADA INITIO$118
- OCALIVA$118
- Ozempic$117
- APRETUDE$110
How this compares
$6,038 in reported general payments places this provider in the 85th percentile of 24 primary care providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $63,778 |
| TrulicityDulaglutide | 28 | $37,034 |
| PerserisRisperidone | 13 | $34,647 |
| JardianceEmpagliflozin | 39 | $33,755 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $22,738 |
| EliquisApixaban | 22 | $21,471 |
| ProzacFluoxetine Hcl | 14 | $8,689 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,504 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,841 |
| Atorvastatin Calcium | 213 | $2,599 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $2,268 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,166 |
| Omeprazole | 66 | $2,116 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,456 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $400 | $63,77854 claims |
| Lilly USA, LLCTrulicity | $17 | $37,03428 claims |
| Indivior Inc.Perseris | $1,281 | $34,64713 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $53 | $31,24141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 24 primary care providers in Hawaii.
Other primary care in Honolulu
- Czamira NordstromHonolulu$10K
- Hye Won KangHonolulu$9K
- John AbesamisHonolulu$6K
- Donita ValdezHonolulu$2K
- Anthone JeonHonolulu$693
- Gayane BejanyanHonolulu$55
- Brittney WhalenKaneohe$5K
- Rizelle TalonWaipahu$5K
- Johanna AuKapolei$5K
- Michelle OjiriHilo$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.